Document is current
Any future updates will be listed below
-
Authors
Zhang, Chuhan
Yu, Shuyan
Li, Size
Wu, Xiaojie
Wei, Qiong
He, Jinjie
Cao, Guoying
Yang, Haijing
Wang, Jingjing
Fujitani, Kohei
Katsube, Takayuki
Zhang, Jing
Dou, Honghong https://orcid.org/0009-0001-3521-5736
-
Clinical Trials BETA
Clinical trials referenced in this document:
chictr2300076607 at Chinese Clinical Trial RegistryDocuments that mention this clinical trial
Pharmacokinetic, Pharmacokinetic/Pharmacodynamic, and Safety Investigations of Cefiderocol in Chinese Healthy Subjects
https://doi.org/10.1007/s12325-025-03147-1
- License Information
-
More Information
Article History
Received: 27 November 2024
Accepted: 13 February 2025
First Online: 13 March 2025
Declarations
:
: Honghong Dou is employee of Ping An-Shionogi Co., Ltd. Kohei Fujitani and Takayuki Katsube are employees of Shionogi & Co., Ltd. Chuhan Zhang received honorarium from Ping An-Shionogi company for a symposium speaker, a study consultant. Shuyan Yu, Size Li, Xiaojie He, Qiong Wei, Jinjie He, Guoying Cao, Haijing Yang, Jingjing Wang, and Jing Zhang have nothing to disclose.
: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of Huashan Hospital, Fudan University (2022 Trial No. 084). The trial is registered with Chinadrugtrials.org.cn (ChiCTR2300076607). All enrolled subjects provided written informed consent before participation.
